# EDGAR Filing Document

**Accession Number:** 0001793602
**File Stem:** 0001178913-23-001109
**Filing Date:** 2023-3
**Character Count:** 7480
**Document Hash:** 2490de778095f569d773980a5319d859
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-23-001109.hdr.sgml**: 20230323

**ACCESSION NUMBER**: 0001178913-23-001109

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230316

**FILED AS OF DATE**: 20230323

**DATE AS OF CHANGE**: 20230323

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Darvish Nissim
- **CENTRAL INDEX KEY:** 0001793602

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38807
- **FILM NUMBER:** 23754476

**MAIL ADDRESS:**
- **STREET 1:** C/O INNOVATE BIOPHARMACEUTICALS, INC.
- **STREET 2:** 8480 HONEYCUTT ROAD, SUITE 120
- **CITY:** RALEIGH
- **STATE:** NC
- **ZIP:** 27615
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Chemomab Therapeutics Ltd.
- **CENTRAL INDEX KEY:** 0001534248
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 813676773
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** KIRYAT ATIDIM, BUILDING 7
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 6158002
- **BUSINESS PHONE:** 972-77-331-0156

**MAIL ADDRESS:**
- **STREET 1:** KIRYAT ATIDIM, BUILDING 7
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 6158002

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Anchiano Therapeutics Ltd.
- **DATE OF NAME CHANGE:** 20180906

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BioCancell Ltd.
- **DATE OF NAME CHANGE:** 20111104

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Darvish Nissim<br><sub>(Last) (First) (Middle)</sub><br>C/O CHEMOMAB THERAPEUTICS LTD.<br>KIRYAT ATIDIM, BUILDING 7<br><sub>(Street)</sub><br>TEL AVIV, L3 6158002<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-03-16 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Chemomab Therapeutics Ltd. [ CMMB ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| American Depositary Shares |  |  |  |  |  |  |  | 1200 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Option to Purchase American Depositary Shares<sup>(2)</sup> | $1.62 | 2023-03-16 |  | A |  | 6857 |  | <sup>(3)</sup> | 2033-03-21 | American Depositary Shares<sup>(1)</sup> | 6857 | $0 | 6857 | D |  |
| Option to Purchase American Depositary Shares<sup>(2)</sup> | $3.53 | 2022-03-07 |  | A |  | 6820 |  | <sup>(4)</sup> | 2032-03-07 | American Depositary Shares<sup>(1)</sup> | 6820 | $0 | 6820 | D |  |
| Option to Purchase American Depositary Shares<sup>(2)</sup> | $27.26 | 2021-04-19 |  | A |  | 11884 |  | <sup>(5)</sup> | 2031-04-19 | American Depositary Shares<sup>(1)</sup> | 11884 | $0 | 11884 | D |  |
| Option to Purchase American Depositary Shares<sup>(2)</sup> | $0.8 | 2016-10-28 |  | A |  | 10123 |  | <sup>(6)</sup> | 2017-10-27 | American Depositary Shares<sup>(1)</sup> | 10123 | $0 | 10123 | D |  |

---

### Footnotes:

(1) Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

(2) No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

(3) These options were granted as per the annual grant of options to directors. These options vest and become exercisable in their entirety on March 16, 2024, subject to the Reporting Person's continued service.

(4) These options vested and became exercisable in their entirety on March 16, 2023. These options were granted as per the annual grant of options to directors.

(5) These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.

(6) The options reported in this row have all vested and are exercisable as of the date hereof, subject to the Reporting Person's continued service.

**Signature:** /s/ Matthew Rudolph, Esq., Attorney-in-Fact for Nissim Darvish  
**Date:** 2023-03-23

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**